Beverly E Sha1, Camlin Tierney2, Xin Sun2, Alice Stek3, Susan E Cohn4, Robert W Coombs5, Barbara Bastow6, Francesca T Aweeka7. 1. Division of Infectious Diseases, Rush University Medical Center, Chicago, IL USA. 2. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA USA. 3. Department of Obstetrics and Gynecology, Los Angeles County and University of Southern California Medical Center, Los Angeles, CA USA. 4. Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, IL USA. 5. Departments of Laboratory Medicine and Medicine, University of Washington, Seattle, WA USA. 6. Social & Scientific Systems, Inc., Silver Spring, MD USA. 7. University of California, San Francisco, San Francisco, CA USA.
Abstract
OBJECTIVE: We studied the pharmacokinetics and pharmacodynamics of boosted soft-gel lopinavir/ritonavir to assess if the area under the plasma concentration versus time curve (AUC) is altered in pregnancy and whether changes in AUC impacted HIV-1 control. METHODS: We enrolled pregnant women ≥13 years of age between 22 to 30 weeks gestation who expected to be on stable lopinavir/ritonavir for ≥8 weeks pre-delivery and ≥24 weeks post-delivery. Pharmacokinetic evaluations for lopinavir and ritonavir occurred at 36 weeks gestation and 6 and 24 weeks postpartum. RESULTS: Ten women underwent intensive pharmacokinetic evaluations for lopinavir and ritonavir at 36 weeks gestation and at 6 and 24 weeks postpartum. Estimated geometric mean (GM) AUC 0-6h (95% CI) for lopinavir were not significantly different at 26.5 (17.0, 41.4) and 41.9 (26.1, 67.5) mcg*hr/mL at 36 weeks gestation and 6 weeks postpartum, respectively (within-subject GM ratio 0.60 (0.25, 1.43); p=0.19). At 36 weeks gestation, 5 of 10 women had viral load <50 copies/mL and at 6 weeks postpartum 5 of 9 had viral load <50 copies/mL. Nine of ten infants for whom data were available were HIV negative. CONCLUSION: Despite below target lopinavir levels (< 52 mcg*hr/mL except at 2 postpartum measurements), women maintained virologic control postpartum. Higher doses of lopinavir/ritonavir during pregnancy may not be necessary in all women.
OBJECTIVE: We studied the pharmacokinetics and pharmacodynamics of boosted soft-gel lopinavir/ritonavir to assess if the area under the plasma concentration versus time curve (AUC) is altered in pregnancy and whether changes in AUC impacted HIV-1 control. METHODS: We enrolled pregnant women ≥13 years of age between 22 to 30 weeks gestation who expected to be on stable lopinavir/ritonavir for ≥8 weeks pre-delivery and ≥24 weeks post-delivery. Pharmacokinetic evaluations for lopinavir and ritonavir occurred at 36 weeks gestation and 6 and 24 weeks postpartum. RESULTS: Ten women underwent intensive pharmacokinetic evaluations for lopinavir and ritonavir at 36 weeks gestation and at 6 and 24 weeks postpartum. Estimated geometric mean (GM) AUC 0-6h (95% CI) for lopinavir were not significantly different at 26.5 (17.0, 41.4) and 41.9 (26.1, 67.5) mcg*hr/mL at 36 weeks gestation and 6 weeks postpartum, respectively (within-subject GM ratio 0.60 (0.25, 1.43); p=0.19). At 36 weeks gestation, 5 of 10 women had viral load <50 copies/mL and at 6 weeks postpartum 5 of 9 had viral load <50 copies/mL. Nine of ten infants for whom data were available were HIV negative. CONCLUSION: Despite below target lopinavir levels (< 52 mcg*hr/mL except at 2 postpartum measurements), women maintained virologic control postpartum. Higher doses of lopinavir/ritonavir during pregnancy may not be necessary in all women.
Entities:
Keywords:
HIV viral load; lopinavir; pharmacokinetics; pregnancy; ritonavir
Authors: J S Lambert; L J Else; V Jackson; J Breiden; S Gibbons; L Dickinson; D J Back; M Brennan; E O Connor; N Boyle; C Fleming; S Coulter-Smith; S H Khoo Journal: HIV Med Date: 2010-08-18 Impact factor: 3.180
Authors: Alice M Stek; Mark Mirochnick; Edmund Capparelli; Brookie M Best; Chengcheng Hu; Sandra K Burchett; Carol Elgie; Diane T Holland; Elizabeth Smith; Ruth Tuomala; Amanda Cotter; Jennifer S Read Journal: AIDS Date: 2006-10-03 Impact factor: 4.177
Authors: Brookie M Best; Alice M Stek; Mark Mirochnick; Chengcheng Hu; Hong Li; Sandra K Burchett; Steven S Rossi; Elizabeth Smith; Jennifer S Read; Edmund V Capparelli Journal: J Acquir Immune Defic Syndr Date: 2010-08 Impact factor: 3.731
Authors: F T Aweeka; A Stek; B M Best; C Hu; D Holland; A Hermes; S K Burchett; J Read; M Mirochnick; E V Capparelli Journal: HIV Med Date: 2009-12-03 Impact factor: 3.180
Authors: Kristine B Patterson; Julie B Dumond; Heather A Prince; Amanda J Jenkins; Kimberly K Scarsi; Ruili Wang; Stephanie Malone; Michael G Hudgens; Angela D M Kashuba Journal: J Acquir Immune Defic Syndr Date: 2013-05-01 Impact factor: 3.731
Authors: Mark Mirochnick; Brookie M Best; Alice M Stek; Edmund Capparelli; Chengcheng Hu; Sandra K Burchett; Diane T Holland; Elizabeth Smith; Sreedhar Gaddipati; Jennifer S Read Journal: J Acquir Immune Defic Syndr Date: 2008-12-15 Impact factor: 3.731
Authors: Silvia Baroncelli; Paola Villani; Marco Floridia; Maria F Pirillo; Clementina M Galluzzo; Maria Cusato; Roberta Amici; Carmela Pinnetti; Francesca Sabbatini; Atim Molinari; Enrica Tamburrini; Mario Regazzi Journal: Ther Drug Monit Date: 2008-10 Impact factor: 3.681